目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Global Immunomodulators Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Global Immunomodulators Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Global Immunomodulators Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Immunomodulators Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Immunosuppressants
4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Immunostimulants
4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Immunomodulators Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Immunomodulators Market: Applicaton Movement Analysis, 2023 & 2030 (USD Million)
5.3. Oncology
5.3.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Respiratory
5.4.1. Respiratory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. HIV
5.5.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Immunomodulators Market: Regional Estimates & Trend Analysis
6.1. Global Immunomodulators Market Share, By Region, 2023 & 2030 (USD Million)
6.2. North America
6.2.1. North America Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. U.S. Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Canada Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4. Mexico
6.2.4.1. Mexico Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. UK Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Germany Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. France Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Italy Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Spain Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Denmark Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Sweden Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Norway Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. China
6.4.2.1. China Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Japan
6.4.3.1. Japan Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. India Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. South Korea
6.4.5.1. South Korea Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. Australia
6.4.6.1. Australia Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Thailand Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Brazil Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Argentina Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Middle East and Africa
6.6.1. Middle East and Africa Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Saudi Arabia
6.6.2.1. Saudi Arabia Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. UAE
6.6.3.1. UAE Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. South Africa
6.6.4.1. South Africa Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Kuwait Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
7.4.1. F. Hoffmann-La Roche Ltd
7.4.1.1. Participant’s Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Recent Developments/ Strategic Initiatives
7.4.2. Amgen Inc.
7.4.2.1. Participant’s Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Recent Developments/ Strategic Initiatives
7.4.3. Abbott
7.4.3.1. Participant’s Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Recent Developments/ Strategic Initiatives
7.4.4. Johnson & Johnson Services, Inc.
7.4.4.1. Participant’s Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Recent Developments/ Strategic Initiatives
7.4.5. Novartis AG
7.4.5.1. Participant’s Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Recent Developments/ Strategic Initiatives
7.4.6. Eli Lilly and Company
7.4.6.1. Participant’s Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Recent Developments/ Strategic Initiatives
7.4.7. Bristol-Myers Squibb Company
7.4.7.1. Participant’s Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Recent Developments/ Strategic Initiatives
7.4.8. Merck & Co., Inc.
7.4.8.1. Participant’s Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Recent Developments/ Strategic Initiatives
7.4.9. Biogen
7.4.9.1. Participant’s Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Recent Developments/ Strategic Initiatives
7.4.10. Pfizer Inc.
7.4.10.1. Participant’s Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Recent Developments/ Strategic Initiatives